Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Torri

Showing results (51-60 of 228) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|November 14, 2018
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpointEliana Rulli, Francesca Ghilotti, Elena Biagioli, et al.
Journal of Proteomics|July 10, 2012
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsEnrico Milan, Chiara Lazzari, Santosh Anand, et al.
Oncology|November 6, 2002
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patientsMario Mandalà, Paolo Lissoni, Gianluigi Ferretti, et al.
Trials|July 29, 2008
Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical TrialsIrene Floriani, Nicole Rotmensz, Elena Albertazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2024
How to Test <i>HER2</i> for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405Andrea Sartore-Bianchi, Silvia Marsoni, Alessio Amatu, et al.
Anticancer Research|April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patientsPamela Biondani, Elena Verzoni, Valter Torri, et al.
Future Oncology (London, England)|July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factorPaolo Grassi, Elena Verzoni, Luca Porcu, et al.
SN Comprehensive Clinical Medicine|August 25, 2020
Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the PandemicOrlando Goletti, Chiara Nessi, Amidio Testa, et al.
European Journal of Internal Medicine|May 9, 2016
Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologistOscar Corli, Andrea A Martoni, Luca Porcu, et al.
American Journal of Clinical Oncology|September 26, 2013
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk FactorsGiuseppe Procopio, Paolo Grassi, Isabella Testa, et al.
Pageof 23

Showing results (51-60 of 228) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|November 14, 2018
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpointEliana Rulli, Francesca Ghilotti, Elena Biagioli, et al.
Journal of Proteomics|July 10, 2012
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsEnrico Milan, Chiara Lazzari, Santosh Anand, et al.
Oncology|November 6, 2002
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patientsMario Mandalà, Paolo Lissoni, Gianluigi Ferretti, et al.
Trials|July 29, 2008
Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical TrialsIrene Floriani, Nicole Rotmensz, Elena Albertazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2024
How to Test <i>HER2</i> for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405Andrea Sartore-Bianchi, Silvia Marsoni, Alessio Amatu, et al.
Anticancer Research|April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patientsPamela Biondani, Elena Verzoni, Valter Torri, et al.
Future Oncology (London, England)|July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factorPaolo Grassi, Elena Verzoni, Luca Porcu, et al.
SN Comprehensive Clinical Medicine|August 25, 2020
Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the PandemicOrlando Goletti, Chiara Nessi, Amidio Testa, et al.
European Journal of Internal Medicine|May 9, 2016
Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologistOscar Corli, Andrea A Martoni, Luca Porcu, et al.
American Journal of Clinical Oncology|September 26, 2013
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk FactorsGiuseppe Procopio, Paolo Grassi, Isabella Testa, et al.
Pageof 23